

Case Study: EUCLID Trial



SITUATION

- EUCLID was the largest study of peripheral artery disease completed to date, and involved enrolling more than 13,500 patients at more than 900 sites in 28 countries.



SOLUTION

- The CEC and Safety clinical program for EUCLID was a team effort that incorporated multiple aspects of clinical event surveillance and adjudication with over 11,000 triggers completed.



IMPACT

- **“I think the most impressive accomplishment of the CEC group has been the commitment to measuring quality in adjudication and improving our processes, as proven by the EUCLID experience,”** said Schuyler Jones, MD, CEC co-director and EUCLID CEC principal investigator.

